OUR RESEARCH
NASH
Targets & Clinical Progress
Posters/Publications
OUR PIPELINE
Pipeline
Clinical Trials
Expanded Access Policy
OUR STORY
Overview
Management Team
Partnership
NEWS
CAREERS
OUR RESEARCH
NASH
Targets & Clinical Progress
Posters/Publications
OUR PIPELINE
Pipeline
Clinical Trials
Expanded Access Policy
OUR STORY
Overview
Management Team
Partnership
NEWS
CAREERS
Posters/Publications
Title
Venue
Type
Date
Fatty Acid Synthase Inhibitor TVB-2640 Reduces Hepatic de Novo Lipogenesis in Males With Metabolic Abnormalities
Hepatology 2020
paper
07/2020
Progressive Reductions in Hepatic DNL with Increasing Doses of TVB-2640, a First-in-Class Pharmacologic Inhibitor of FASN
Keystone Symposium on Organ Crosstalk in Obesity and NAFLD
poster
01/2018
First in human study of the first-in-class fatty acid synthase (FASN) inhibitor TVB-2640
AACR Annual Meeting
oral
04/2017